Sélection de la langue

Search

Sommaire du brevet 2108794 

Énoncé de désistement de responsabilité concernant l'information provenant de tiers

Une partie des informations de ce site Web a été fournie par des sources externes. Le gouvernement du Canada n'assume aucune responsabilité concernant la précision, l'actualité ou la fiabilité des informations fournies par les sources externes. Les utilisateurs qui désirent employer cette information devraient consulter directement la source des informations. Le contenu fourni par les sources externes n'est pas assujetti aux exigences sur les langues officielles, la protection des renseignements personnels et l'accessibilité.

Disponibilité de l'Abrégé et des Revendications

L'apparition de différences dans le texte et l'image des Revendications et de l'Abrégé dépend du moment auquel le document est publié. Les textes des Revendications et de l'Abrégé sont affichés :

  • lorsque la demande peut être examinée par le public;
  • lorsque le brevet est émis (délivrance).
(12) Brevet: (11) CA 2108794
(54) Titre français: UTILISATION DE TORASEMIDE DANS LE TRAITEMENT D'OEDEMES CEREBRAUX
(54) Titre anglais: USE OF TORASEMIDE FOR THE TREATMENT OF BRAIN OEDEMAS
Statut: Durée expirée - au-delà du délai suivant l'octroi
Données bibliographiques
(51) Classification internationale des brevets (CIB):
  • A61K 31/64 (2006.01)
(72) Inventeurs :
  • BOELKE, TIM (Allemagne)
  • KLING, LOTHAR (Allemagne)
  • KOENIG, REINHARD (Allemagne)
(73) Titulaires :
  • BOEHRINGER MANNHEIM GMBH
  • MEDA AB
(71) Demandeurs :
  • BOEHRINGER MANNHEIM GMBH (Allemagne)
  • MEDA AB (Suède)
(74) Agent: NORTON ROSE FULBRIGHT CANADA LLP/S.E.N.C.R.L., S.R.L.
(74) Co-agent:
(45) Délivré: 2003-06-24
(86) Date de dépôt PCT: 1992-04-22
(87) Mise à la disponibilité du public: 1992-11-12
Requête d'examen: 1999-04-20
Licence disponible: S.O.
Cédé au domaine public: S.O.
(25) Langue des documents déposés: Anglais

Traité de coopération en matière de brevets (PCT): Oui
(86) Numéro de la demande PCT: PCT/EP1992/000884
(87) Numéro de publication internationale PCT: EP1992000884
(85) Entrée nationale: 1993-10-19

(30) Données de priorité de la demande:
Numéro de la demande Pays / territoire Date
P 41 13 820.1 (Allemagne) 1991-04-27

Abrégés

Abrégé anglais


-12-
Summary
Use of torasemide for the treatment of brain
oedemas and orally and parenterally administerable
torasemide.

Revendications

Note : Les revendications sont présentées dans la langue officielle dans laquelle elles ont été soumises.


11
CLAIMS
Use of 1-isopropyl-3-[(4-m-toluideno-3-pyridyl)-sulfonyl] urea
or of its pharmacologically acceptable salts for the manufacture of
medicaments for the treatment of brain oedemas.
2. Use according to claim 1 for the manufacture of medicaments for
the treatment of brain oedemas, which occur as a result of severe skull-brain
traumas, cerebral ischaemia, strokes, metastases or epileptic fits.
3. Use according to claim 1 for the manufacture of medicaments for
the treatment of cytotoxic brain oedemas initiated by hypoosmolar
hyperhydration.
4. A pharmaceutical composition for the treatment of brain oedemas
comprising a physiologically acceptable amount of 1-isopropyl-3-[(4-m-
toluideno-3-pyridyl)-sulfonyl] urea or a pharmacologically acceptable salt
thereof, in association with a pharmaceutically acceptable carrier.
5. A pharmaceutical composition for the treatment of brain
oedemas, which occur as a result of severe skull-brain traumas, cerebral
ischaemia, strokes, metastases or epileptic fits, comprising a physiologically
acceptable amount of 1-isopropyl-3-[(4-m-toluideno-3-pyridyl)-sulfonyl]
urea or a pharmacologically acceptable salt thereof, in association with a
pharmaceutically acceptable carrier.

12
6. A pharmaceutical composition for the treatment of brain oedemas
initiated by hypoosmolar hyperhydration, comprising a physiologically
acceptable amount of 1-isopropyl-3-[(4-m-toluideno-3-pyridyl)-sulfonyl]
urea or a pharmacologically acceptable salt thereof, in association with a
pharmaceutically acceptable carrier.
7. 1-isopropyl-3-[(4-m-Toluideno-3-pyridyl)-sulfonyl] urea or a
pharmacologically acceptable salt thereof for use in the treatment of brain
oedemas.
8. 1-isopropyl-3-[(4-m-Toluideno-3-pyridyl)-sulfonyl] urea or a
pharmacologically acceptable salt thereof for use in the treatment of brain
oedemas, which occur as a result of severe skull-brain traumas, cerebral
ischaemia, strokes, metastases or epileptic fits.
9. 1-isopropyl-3-[(4-m-Toluideno-3-pyridyl)-sulfonyl] urea or a
pharmacologically acceptable salt thereof for use in the treatment of brain
oedemas initiated by hypoosmolar hyperhydration.

Description

Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.


CA 02108794 2002-09-13
Use of Torasemide for the Treatment of Brain Oedemas
The invention relates to the use of torasemide for the treatment of the
swellings of nerve and glia cells in the case of brain oedemas which arise as
a
result of e.g. skull-brain traumas and metastases and orally and parenterally
administrable torasemide.
In accordance with the invention there is provided use of 1-isopropyl-3-
[(4-m-toluideno-3-pyridyl)-sulfonyl] urea or oI its pharmacologically
acceptable salts for the manufacture of medicaments for the treatment of brain
oedemas.
In accordance with another aspect of the invention there is provided of a
pharmaceutical composition for the treatment of~ brain oedemas comprising a
physiologically acceptable amount of 1-isopropyl-3-[(4-m-toluideno-3-
pyridyl)-sulfonyl] urea or a pharmacologically acceptable salt thereof, in
association with a pharmaceutically acceptable carrier.
In accordance with still another aspect of~ the invention there is provided
1-isopropyl-3-[(4-rn-Toluideno-3-pyridyl)-sulfonyl] urea or a
pharmacologically acceptable salt thereof for use in the treatment of brain
oedemas.
In particular embodiments of the afore-mentioned aspects of the
invention the brain oedemas are those resulting from severe skull-brain
traumas, cerebral ischaemia, strokes, metastases, epileptic fits, or initiated
by
hypoosmolar hyperhydration.

CA 02108794 2002-09-13
Torasemide, chemical designation 1-isopropyl-3-[(4-m-toluideno-3-
pyridyl)-sulfonyl]urea is known as a loop diuretic in the case of the systemic
administration of which urine volumes and electrolyte excretion increase
linearly with the logarithm of the torasemide dose.
In in vitro investigations, it could be shown that torasemide clearly
reduces the acidosis-induced swelling of C'.6 glioma cells. Furthermore, in
the
case of in vivo investigations on rats, it was ascertained that torasemide as
able
to lower the intracranial pressure (ICP) in cytotoxic brain oedema initiated
by
hypoosmolar hyperhydration.
An acidosis occurs in the brain in the case of cerebral ischaemia, in the
case of skull-brain traumas, in the case of epileptic attacks, as well as
under
other pathophysiological conditions. In the case. of cerebral ischaemia, the
pH
value can decrease to 6.5 to 6.0, under hyperglycaemic conditions the acidosis
can be even more marked.

210~'~04
_3_
As~a result of the. acidosis and of the reduced
energy metabolism involved therewith, a net inflow
of N~+ and CI-dons into the cells taken place,
whereby' the intracellular increase of the osmolarity
leads to a corresponding warter movement and .thus to
a cell swelTLi.ng,.
For diuretics such as e,.g~ bumetanide and
furosemide which act in the kidney like torasemide
via- the NaG1 KCl. co-transport, it. was shown tha°t.
theyr were not able. to influence an experimentally
increased intracrani.al pressure (s.ee the article
"Effe.ct of furosemide~, bumetanide and mannitol on
intracranial pre~s~ure in expermmental brain edema
of the ran" by C., Plangger arid H,. Volkl in Zent b1
Neurochir 50: 142-144,; 1.989):" In this regardr it
was' surprising that,. o~ith torasemide,., a lowering of
the. increased intracranial pressure could be observed"
The effectivanes~s o.f torasemide in the reduction
of the swelling ccf glia cells or in the. _lowering of
20. the' TCP is~ .shown by the.. investigations described in
more; detail in the following and illustrated by
Fi:gure~.~~
The Fig" 1 and 2. show the chronological caurae
of an in vitro acidasia-induced sell swelling of C,6
glioma ceTls~ after incubat~:an with torasemide or
in the~case:of control experiments without verum
administration,. The chronological change of the

-4-
vitality of the C6 glioma cells iii the Case of these
experiments is illustrated in Fig" 3,. The figP ~, to,
6 SNOW the chronological changes of the ICP, of the
average systemic arterial blood pressure and of
the cerebral perfusion pressure in rats after
ind~zction of a brain oedema in two experimental
Series'" whereby in one experimental series torasemide
was' ~,tlmi:nister.ed intravenously and in the other
(control) experimental series iso.to.ni.c common salt
TO solution,.
Tn the:case: of the in vitro investigations
concerning the influewce of torasemide on acidosis;,
induced cell swelling,. C6 glioma cells with glia-
sEpecsfic propertaes~ were. used, The glia cells grew
I5 as monolayer in Petr~dishes under conventional
culture conditions with 95~ ambient air" 5g~ C02 and
at a temperature of.3~oC., Culture medium was
DuTbecco's minimal essential medium (DM~"I) with
25 mM bicarbonate as' buffer, Furthermore, the medium
20 contained 10~ foetal calf serum (FCS), as well as
100 TU/ml of penicillin G and 50 ~,~,g/ml strepto-
m~cin, Far the carrying out of an experiment" the
culls were~harvested from 6 culture dishes wibh
trgps~in, washed Mice with FCS-fp~ee medium and
25 s~ubsequentl~r introduced into an experimental chamber,.
The chamber ensured a homogeneous stability of the
individual suspension for several hours, as' well as

2~~8'~~~
5-
the: monitOrlrig Of the medium by continuous recording
Of the pH value, of the oxygen partial,pressure and
of the temperatures The determination of the cell
volume took place quantitative~.y with the help: of
a flowthrough eytomete~r according to the Coulter
process. In addition, the apgaretus employed. hydro-
dynamic focussing of the: particles for the improvement
of the measurement exa.ctitude,. In this way,. cha~nge~
of the cell volume of [ 1~ can be detected with
certaint~r" The: vitadli.ty of the cells was determined
flowthro.ugh-c~rtometrically bg determina.tion by
-propidium iadide~
C&~rr~ing out of experiment: The cell volume" as well
as the cell vitahity,,were first examined in a control
T5 phase (45 min) for their constant course,. Furthermore"
the osmolarity of the medium was determined In addition,
it was:ascertained in parallel experiments tha-t,, in the
case of exclusive addition of t.orasemide, no significant
change of the cell volume and no influencing of the?
vitality of the: C.6 glinma cells took place".The cell
sFwelling was~produced.after the control phase by
lowering of the pH valu~ to 6,.6 or 5,.0, ~espectivaZy,
with the help~of isotonic lactic acid" The,pCa2 of
the chamber w.aa simultaneously increased to 80 to
2'S TOO mm H~, The eRperimental period amounted to 60
minutely Tn each case,,2 parallel experiments were
carri$d out at pH 6"2.and. 5,0,. In the case of in

_6_
each case one.experiment, torasemide was~added to
the medium in an end concentration of l~mM 15 minutes
before the acidification. The other experiment served
as control,.
S The results axe set out in Fig, l and 2,, in which
the: cell volume (in ~ of the starting value) is plotted
against the experimental period,. Furthermore,; in each
ca.s~e the time span is given during which the pH value
had sunk to 6, 2= or.~ 5,,0;" respectivel~r,. The time: spans
T.0 between the: two experiments, w~,thin which the
experimental data: obtained under torasemide were
sign3ficantTy different (,p < 0,.01) from the control,
are also ma~cked;. The cell volume values plotted in
the curves are. arithmetic averages ($).+ w;EM~ The:
15 results clearly show the inhibition ~of the cell
swelling by' toravsemide, As Fig,. 3 shaves,; .torasemide
furthermore has peruse no influence on the vitality
of C6 glioma. cells,. In Fi:g,. 3 is shaven the change of
the vitality of the C6 ghioma~ cslls~ over the experi-
20 mental period, Fur.~thermo.re, the time span is marked
during which the pf3 value had sunk to 5,.0, One sees
from the curves~~ that admittedly the pH sink3:ng but
not the torasemido add~.t~.on hae~ an influence on the
vita.Tity~",. The. results of. the described. experiments
~5 ~wexe. ana~lysed.~for significance with the help of
the. variance analysis and the Kruskal-Wallis test
for the intergro.up comparison,.

21a8"~9~
_7_.
The action of torase.mide in the case of brain
Oedema wag investigated in vivo in the pharmacolog-
ical model of the cytotoxic brain oedema of the rat"
In the case of 150 to 240: g weighted male rats, for
the continuous detection of the s~:stemic arterial
blood pressurev, a catheter was inserted into the
right a~rteria femoralis~ a.nd measured bar means of a
Could Fl0 E2 blood. pressure transformer, of a S~iemens
m~rnitor and o.f a:2-canal recorder (Zinseis L~650~
and recorded,,- For the continuous detection of the=
TCg, a Wick catheter. was~introduced. through a
" trepa.naaion of the; left front side of the:skullP
The: IOP waw,measured and recorded bg means- of an
eTect.romagnetic Statham transformer P'23 Db~. which
was' connected with a He~:Tige el.ectromanome~er, and
of a 2-canal. recorder- (Zins.eis~ I~ 650).. Iri order to
exclude a possible diuretic effect" the rats wexee
functionally nephrectomis~ed.,,
Carrying out the: experiment z For. the inducing cr:f
the brain oedema, T00 ml bidistilled~;wate~~;~kg ..b~5dy .
weight was. infused at.0"5 ml/,min into the right
vane ~ugularis~~,. ~I~,rea.fter ~warer ink~cted l00 mg
toraeemide/kg body weight 3.n l0 ml liqua,d/kg bod~r
weight and in a parallel exp7eriment 10 ml of isn.tonic
2.5. ~~mmo~n salt sohutiQ.n (;pl.acebo)/kg body weight, LCP
and blood prevaure. w.e.re: continuously recorded for.
3 hours after admin~~.tr~a.ticrn of torasemide o.r

210~'~~~
_8_
placebo, 6 rats received a torasemide injections
7 rats received placebo,
The evaluated results of the TCP and blood pressure
measurements are set out in Fig, 4 a:nd 5, respect~:valy,
Fig,. 4 shows that the TCP in the case of the xats~
treated with toras.emide was, as every point o:f time,
lower than in the case of animals treated with placebo
in the para:;llel experiment,. However" the differences'
were. not statistically significant, Therefore, for the
ve~xification of the finding, the cerebral perfusion
pressure was also determined (the cerebral.perfusian
pressure iw equal to the difference between the
systemic average. arterial blood pre.ssure~ and the: ICP),
It way thereby found. (see Fig, 6) that the values
thereof 90 and T00.minutes; ofter the~administration
of tora~s~mide were. significantly higher' than in the
control graup, This was mainly to be attributed to
the much Lower TCP values.~in the rats~treated with
tara~semide" 'In Fig, 4 t:o 6 are. plot~tad arithmetic
average values (~c)~ -~ Wit. against the: time, The testing
far significant differences between the exp~.riinente~.
groups treated with taras~emaLde. arid placebo took place
by means a~f a one-sided Student t-test for unpaired
data,.
25. ~ummarising",it can be raids Not only the. in vitro.
experiments with C6 glioma cells but also the i~a vivcov
experiments on rats show that torasemide acts

~1087~~
-9-
swelling-inhibitingly or pressure lowering in tl~e
Case of induced swelling of the glia cells and
increased ZCl'~. Torasemide is,, therefore, also
favourable because - as has been:escertained in
experiments with C6 glioma cells (see above) --
torasemide does. no.t inpair the. vitality of the- gT.ia
cells; this is reduced in the. same experimental
procedure e.,g" by amiloride. Possible causes for~the
pharmacological action observed with torasemide but
1~~ not with e,.g, furosemide and bumetanide is the high
lipophilia of torasemide (octanol/H20 coefficient:
/ 0.71., a
The preparation of torasemide takes place according
to the proces<:s described in the Patent specification
DE 25 l6 025 C2,.
On the basis of its high bioavailability~; tora-
semide.can be used in equivalent dose not only orall~r
but also parenterall~ for the therapy of brain oedemas
of various genesis..
~20 Eorr the. preparation of medicaments to be adminis-
tered orally, torasemide is mired in per se, l~nown
manner. with suitable pharmaceutical carrie r substances,
aroma, flavouring and colouring rnater3als~and formed,
f.or example, as tablets or d~agees or, with the
addition of appropriate adjuvants,, suspended or
dissolved in water or oil." such as e,,g" olive oil,

_10_.
For the production of a pharmaceutical preparation
to be administered parenterally~ torasemide~, possibly
in the form of its pharmacologically acceptable salts,
is suspended or dissolved in water in per se known
way' with addition of appropriate adjuvants~ srch as'
e-..g.. emul~ifiera-,
morasemide is administered in amounts between 5
and 40 mg per. dayv
An exemplary formulation for a tablet with lCl mg
of active material is composed as followa~:
~torasemide 10,0 mg '
hactose .. 1 H20 116"0 mg
maize ~ta.rch 32,.0 mg
colloidal silicon dioxide 1,2 mg
1.5 magnesium stearate: 0,4 - 1,0 mg
weight of a. ta~blea. 159.6 - 160,2 mg
An exemplary formulation for a pharmaceutical
preparation to be administered parenterallg with 10 mg
of active material. is composed as~follows:
sodium tora~semide= 10,631 mg
e~odium. hydrox~.de:: 0,05 mg
tromeatamoT (,2-amino-2-hydraacymethy~l-.~ 025 m
f."3-propanediol) ~ g
macrogol (polye.thylena glycols) 225,00 mg
2'S wa?ter 1804"069 mg
ni trrogen q's,~

Dessin représentatif

Désolé, le dessin représentatif concernant le document de brevet no 2108794 est introuvable.

États administratifs

2024-08-01 : Dans le cadre de la transition vers les Brevets de nouvelle génération (BNG), la base de données sur les brevets canadiens (BDBC) contient désormais un Historique d'événement plus détaillé, qui reproduit le Journal des événements de notre nouvelle solution interne.

Veuillez noter que les événements débutant par « Inactive : » se réfèrent à des événements qui ne sont plus utilisés dans notre nouvelle solution interne.

Pour une meilleure compréhension de l'état de la demande ou brevet qui figure sur cette page, la rubrique Mise en garde , et les descriptions de Brevet , Historique d'événement , Taxes périodiques et Historique des paiements devraient être consultées.

Historique d'événement

Description Date
Inactive : Périmé (brevet - nouvelle loi) 2012-04-22
Lettre envoyée 2009-08-05
Lettre envoyée 2009-07-15
Inactive : Transfert individuel 2009-05-14
Inactive : Lettre officielle 2009-05-01
Accordé par délivrance 2003-06-24
Inactive : Page couverture publiée 2003-06-23
Préoctroi 2003-04-03
Inactive : Taxe finale reçue 2003-04-03
Un avis d'acceptation est envoyé 2002-10-21
Un avis d'acceptation est envoyé 2002-10-21
month 2002-10-21
Lettre envoyée 2002-10-21
Inactive : Approuvée aux fins d'acceptation (AFA) 2002-10-09
Modification reçue - modification volontaire 2002-09-13
Inactive : Dem. de l'examinateur par.30(2) Règles 2002-05-14
Lettre envoyée 1999-07-27
Inactive : Transferts multiples 1999-05-21
Inactive : Dem. traitée sur TS dès date d'ent. journal 1999-05-11
Lettre envoyée 1999-05-11
Inactive : Renseign. sur l'état - Complets dès date d'ent. journ. 1999-05-11
Exigences pour une requête d'examen - jugée conforme 1999-04-20
Toutes les exigences pour l'examen - jugée conforme 1999-04-20
Demande publiée (accessible au public) 1992-11-12

Historique d'abandonnement

Il n'y a pas d'historique d'abandonnement

Taxes périodiques

Le dernier paiement a été reçu le 2003-03-24

Avis : Si le paiement en totalité n'a pas été reçu au plus tard à la date indiquée, une taxe supplémentaire peut être imposée, soit une des taxes suivantes :

  • taxe de rétablissement ;
  • taxe pour paiement en souffrance ; ou
  • taxe additionnelle pour le renversement d'une péremption réputée.

Les taxes sur les brevets sont ajustées au 1er janvier de chaque année. Les montants ci-dessus sont les montants actuels s'ils sont reçus au plus tard le 31 décembre de l'année en cours.
Veuillez vous référer à la page web des taxes sur les brevets de l'OPIC pour voir tous les montants actuels des taxes.

Titulaires au dossier

Les titulaires actuels et antérieures au dossier sont affichés en ordre alphabétique.

Titulaires actuels au dossier
BOEHRINGER MANNHEIM GMBH
MEDA AB
Titulaires antérieures au dossier
LOTHAR KLING
REINHARD KOENIG
TIM BOELKE
Les propriétaires antérieurs qui ne figurent pas dans la liste des « Propriétaires au dossier » apparaîtront dans d'autres documents au dossier.
Documents

Pour visionner les fichiers sélectionnés, entrer le code reCAPTCHA :



Pour visualiser une image, cliquer sur un lien dans la colonne description du document (Temporairement non-disponible). Pour télécharger l'image (les images), cliquer l'une ou plusieurs cases à cocher dans la première colonne et ensuite cliquer sur le bouton "Télécharger sélection en format PDF (archive Zip)" ou le bouton "Télécharger sélection (en un fichier PDF fusionné)".

Liste des documents de brevet publiés et non publiés sur la BDBC .

Si vous avez des difficultés à accéder au contenu, veuillez communiquer avec le Centre de services à la clientèle au 1-866-997-1936, ou envoyer un courriel au Centre de service à la clientèle de l'OPIC.


Description du
Document 
Date
(yyyy-mm-dd) 
Nombre de pages   Taille de l'image (Ko) 
Page couverture 2003-05-20 1 24
Page couverture 1994-06-17 1 90
Revendications 1994-06-17 1 43
Description 1994-06-17 9 559
Description 2002-09-12 10 332
Abrégé 1994-06-17 1 7
Dessins 1994-06-17 6 49
Revendications 2002-09-12 2 61
Rappel - requête d'examen 1998-12-22 1 116
Accusé de réception de la requête d'examen 1999-05-10 1 179
Avis du commissaire - Demande jugée acceptable 2002-10-20 1 163
Courtoisie - Certificat d'enregistrement (document(s) connexe(s)) 2009-07-14 1 102
Correspondance 2003-04-02 2 42
PCT 1993-10-18 35 1 046
Correspondance 2009-04-30 1 16
Correspondance 2009-08-04 1 11
Correspondance 2009-05-06 2 72
Taxes 1997-03-23 1 68
Taxes 1996-03-21 1 73
Taxes 1995-04-02 1 73
Taxes 1994-03-23 1 111